{Reference Type}: Journal Article
{Title}: PTP1B Inhibition Improves Mitochondrial Dynamics to Alleviate Calcific Aortic Valve Disease Via Regulating OPA1 Homeostasis.
{Author}: Liu F;Chen J;Hu W;Gao C;Zeng Z;Cheng S;Yu K;Qian Y;Xu D;Zhu G;Zhao J;Liu X;Wang J;Liu F;Chen J;Hu W;Gao C;Zeng Z;Cheng S;Yu K;Qian Y;Xu D;Zhu G;Zhao J;Liu X;Wang J;
{Journal}: JACC Basic Transl Sci
{Volume}: 7
{Issue}: 7
{Year}: Jul 2022
{Factor}: 9.531
{DOI}: 10.1016/j.jacbts.2022.03.002
{Abstract}: There are currently no pharmacological therapies for calcific aortic valve disease (CAVD). Here, we evaluated the role of protein tyrosine phosphatase 1B (PTP1B) inhibition in CAVD. Up-regulation of PTP1B was critically involved in calcified human aortic valve, and PTP1B inhibition had beneficial effects in preventing fibrocalcific response in valvular interstitial cells and LDLR-/- mice. In addition, we reported a novel function of PTP1B in regulating mitochondrial homeostasis by interacting with the OPA1 isoform transition in valvular interstitial cell osteogenesis. Thus, these findings have identified PTP1B as a potential target for preventing aortic valve calcification in patients with CAVD.